NIDEK launches MP-3 Microperimeter

NewsGuard 100/100 Score

NIDEK CO., LTD., a global leader in the design, manufacture, and distribution of ophthalmic, optometric, and lens edging equipment, is pleased to announce the launch of the MP-3 Microperimeter.

Assessment of retinal morphology has advanced significantly due to the introduction of Optical Coherence Tomography into clinical practice. Advances in the functional evaluation of retinal pathology are due to the use of the microperimeter. The MP-3 measures local retinal sensitivity for functional assessment of the retina. The results can be displayed over a color fundus image, correlating retinal anatomy to retinal function.

For enhanced clinical assessment, the MP-3 now includes a wider range of stimulus intensity, from 0 to 34 dB, compared to the MP-1.

The MP-3 measures perimetric threshold values, even for normal eyes.

A maximum stimulus luminance of 10,000 asb* allows evaluation of low-sensitivity.

The NIDEK auto tracking and auto alignment functions provide more accurate measurements increasing patient and operator comfort and efficiency. These functions allow easy follow-up and  reduce variations between examiners, resulting in well-aligned follow up exams.

Retinal morphology can be evaluated with the 12-megapixel fundus camera included the MP-3 unit which acquires high resolution images of retinal pathology and allows easy image acquisition.

*Complies with the ISO 12866 requirements.

For further information contact:
International Planning Dept.,
NIDEK CO., LTD.
Email: [email protected]

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cytokine interferon-gamma can be a disease-modifying therapeutic target in multiple system atrophy